NCT05642611: ICE COMPRESS

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

Recruiting now Phase 3 Last updated 16 April 2026

What this trial tests

Phase 3 trial testing Biospecimen Collection in Malignant Solid Neoplasm in 777 participants. Currently enrolling.

Timeline

6 June 2023

Primary endpoint
1 August 2030

30 August 2031

Quick facts

Lead sponsor	SWOG Cancer Research Network
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	777
Start date	6 June 2023
Primary completion	1 August 2030
Estimated completion	30 August 2031
Sites	29 locations across United States

Drugs / interventions tested

• Biospecimen Collection — full drug profile →
• Cryocompression Therapy
• Pneumatic Compression Therapy
• Pneumatic Compression Therapy
• Quality-of-Life Assessment
• Questionnaire Administration

Conditions studied

• Malignant Solid Neoplasm — all drugs for Malignant Solid Neoplasm →

Sponsor

SWOG Cancer Research Network

Who can join

18 and older, any sex, with Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase III trial compares the effect of 3 study approaches in preventing chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel or docetaxel, can cause a nerve disorder called peripheral neuropathy, which can cause numbness, tingling, or pain in the arms and legs. The 3 study approaches will use a device, called the Paxman Limb Cryocompression System, made of wraps that cool and/or compress the arms and legs. This study may help researchers determine if any of the study approaches are able to prevent taxane chemotherapy from causing peripheral neuropathy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Quantitation of Plasma Proteins to Predict Taxane-Induced Peripheral Neuropathy.
   Nguyen-Hoang N, Liu Y, Henry NL, Pai MP, et al · · 2025 · cited 2× · PMID 39889244 · DOI 10.1200/po-24-00380
2. Safety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy.
   Bandla A, Wong R, Santhanakrishnan P, Magarajah G, et al · · 2025 · cited 1× · PMID 39937296 · DOI 10.1007/s00520-024-08982-6